Market Closed -
Nasdaq Stockholm
11:29:36 2024-04-26 am EDT
|
5-day change
|
1st Jan Change
|
232
SEK
|
-2.36%
|
|
-5.92%
|
+23.27%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,689
|
4,945
|
2,823
|
5,191
|
12,243
|
15,247
|
-
|
-
|
Enterprise Value (EV)
1 |
1,607
|
4,602
|
2,638
|
4,989
|
12,076
|
15,008
|
14,759
|
14,438
|
P/E ratio
|
-10.5
x
|
-45.1
x
|
-32.8
x
|
-75.9
x
|
50.3
x
|
89.2
x
|
48.8
x
|
32.2
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
0.42%
|
-
|
Capitalization / Revenue
|
10.9
x
|
27.3
x
|
13.3
x
|
15.8
x
|
20.7
x
|
17.8
x
|
12.8
x
|
9.87
x
|
EV / Revenue
|
10.3
x
|
25.4
x
|
12.4
x
|
15.2
x
|
20.4
x
|
17.5
x
|
12.4
x
|
9.35
x
|
EV / EBITDA
|
-10.7
x
|
-46.7
x
|
-32.7
x
|
-77.3
x
|
867
x
|
76.6
x
|
40.6
x
|
23.7
x
|
EV / FCF
|
-9,536,783
x
|
-44,704,928
x
|
-30,380,063
x
|
-99,415,185
x
|
-633,019,249
x
|
-
|
44,563,171
x
|
43,099,454
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
-0%
|
-0%
|
-
|
0%
|
0%
|
Price to Book
|
13.6
x
|
12.4
x
|
10.6
x
|
19.3
x
|
22.6
x
|
22.7
x
|
17.2
x
|
-
|
Nbr of stocks (in thousands)
|
51,956
|
63,723
|
64,162
|
64,521
|
65,056
|
65,721
|
-
|
-
|
Reference price
2 |
32.50
|
77.60
|
44.00
|
80.45
|
188.2
|
232.0
|
232.0
|
232.0
|
Announcement Date
|
2/26/20
|
2/17/21
|
2/17/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
155.5
|
180.9
|
212.9
|
328.8
|
591.1
|
856.8
|
1,188
|
1,545
|
EBITDA
1 |
-150.4
|
-98.56
|
-80.67
|
-64.54
|
13.93
|
196
|
363.8
|
609
|
EBIT
1 |
-158.1
|
-98.56
|
-80.67
|
-64.54
|
13.93
|
186.8
|
356.5
|
598.5
|
Operating Margin
|
-101.67%
|
-54.5%
|
-37.89%
|
-19.63%
|
2.36%
|
21.8%
|
30%
|
38.74%
|
Earnings before Tax (EBT)
1 |
-158.3
|
-99
|
-81.84
|
-64.69
|
15.75
|
186
|
357.5
|
597
|
Net income
1 |
-161.1
|
-101.4
|
-85.53
|
-68.17
|
245
|
174
|
311.4
|
474
|
Net margin
|
-103.58%
|
-56.07%
|
-40.18%
|
-20.73%
|
41.45%
|
20.31%
|
26.2%
|
30.68%
|
EPS
2 |
-3.100
|
-1.720
|
-1.340
|
-1.060
|
3.740
|
2.600
|
4.757
|
7.200
|
Free Cash Flow
|
-168.5
|
-102.9
|
-86.84
|
-50.19
|
-19.08
|
-
|
331.2
|
335
|
FCF margin
|
-108.36%
|
-56.91%
|
-40.79%
|
-15.26%
|
-3.23%
|
-
|
27.87%
|
21.69%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
91.03%
|
55.01%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
106.38%
|
70.68%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
0.9800
|
-
|
Announcement Date
|
2/26/20
|
2/17/21
|
2/17/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
61.4
|
66.34
|
74.6
|
84.62
|
103.2
|
119.7
|
140.4
|
158.2
|
172.7
|
184.4
|
200
|
220.1
|
246.9
|
263.2
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-21.77
|
-16.46
|
-14.9
|
-13.94
|
-19.28
|
0.768
|
5.952
|
14.87
|
-7.658
|
32.29
|
38.7
|
49.2
|
66.7
|
80.7
|
Operating Margin
|
-35.46%
|
-24.8%
|
-19.97%
|
-16.47%
|
-18.68%
|
0.64%
|
4.24%
|
9.4%
|
-4.43%
|
17.51%
|
19.35%
|
22.35%
|
27.01%
|
30.66%
|
Earnings before Tax (EBT)
|
-22.05
|
-16.67
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-24.2
|
-16.37
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-39.42%
|
-24.68%
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/17/22
|
5/4/22
|
7/14/22
|
10/27/22
|
2/16/23
|
4/27/23
|
7/13/23
|
10/26/23
|
2/15/24
|
4/25/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
81.7
|
343
|
185
|
201
|
167
|
239
|
488
|
809
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-168
|
-103
|
-86.8
|
-50.2
|
-19.1
|
-
|
331
|
335
|
ROE (net income / shareholders' equity)
|
-80%
|
-38.8%
|
-25.7%
|
-25.5%
|
60.2%
|
28%
|
32.4%
|
37%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
2.390
|
6.260
|
4.140
|
4.170
|
8.310
|
10.20
|
13.50
|
-
|
Cash Flow per Share
|
-
|
-
|
-1.300
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
4.23
|
2.66
|
3.42
|
2.23
|
0.82
|
8
|
7.12
|
14
|
Capex / Sales
|
2.72%
|
1.47%
|
1.6%
|
0.68%
|
0.14%
|
0.93%
|
0.6%
|
0.91%
|
Announcement Date
|
2/26/20
|
2/17/21
|
2/17/22
|
2/16/23
|
2/15/24
|
-
|
-
|
-
|
Average target price
292.7
SEK Spread / Average Target +26.15% Consensus |
1st Jan change
|
Capi.
|
---|
| +23.27% | 1.39B | | -4.66% | 86.13B | | +1.32% | 39.82B | | -19.27% | 30.42B | | +57.86% | 25.23B | | -16.09% | 15.36B | | -9.14% | 11.95B | | -17.69% | 11.6B | | -43.00% | 11.51B | | +5.24% | 8.71B |
Biopharmaceuticals
|